Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018140563) USE OF APOE MIMETIC PEPTIDES FOR REDUCING THE LIKELIHOOD OF EPILEPTOGENESIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/140563 International Application No.: PCT/US2018/015165
Publication Date: 02.08.2018 International Filing Date: 25.01.2018
IPC:
A61K 38/08 (2006.01) ,A61K 38/17 (2006.01) ,C07K 7/00 (2006.01) ,A61P 25/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
08
Antiepileptics; Anticonvulsants
Applicants:
DUKE UNIVERSITY [US/US]; 2812 Erwin Road, Suite 306 Durham, North Carolina 27705, US
Inventors:
LASKOWITZ, Daniel T.; US
MACE, Brian E.; US
KOLLS, Bradley; US
Agent:
MURPHY, Sherry, L.; Myers Bigel, P.A. P.O. Box 37428 Raleigh, North Carolina 27627, US
Priority Data:
62/450,69326.01.2017US
Title (EN) USE OF APOE MIMETIC PEPTIDES FOR REDUCING THE LIKELIHOOD OF EPILEPTOGENESIS
(FR) UTILISATION DE PEPTIDES MIMÉTIQUES D'APOE POUR RÉDUIRE LA PROBABILITÉ D'ÉPILEPTOGENÈSE
Abstract:
(EN) Provided herein is a method for reducing the likelihood of epileptogenesis in a subject (e.g., a subject at risk thereof), comprising administering to said subject (e.g., a human subject) an effective amount a peptide of Formula I, or a pharmaceutically acceptable salt thereof.
(FR) L'invention concerne un procédé pour réduire la probabilité d'épileptogenèse chez un sujet (par exemple, un sujet à risque de présenter celle-ci), comprenant l'administration audit sujet (par exemple, un sujet humain) d'une quantité efficace d'un peptide de formule I, ou d'un sel pharmaceutiquement acceptable de celui-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)